O-2694

O-2694 is a drug that acts as a potent and selective agonist for the cannabinoid receptor CB2, with reasonable selectivity over the psychoactive CB1 receptor, though with some variation between species. It has analgesic effects in animal studies, particularly against "atypical" pain types such as hyperalgesia and allodynia.

Pharmacology

O-2694 is a cannabinoid receptor agonist. It has a high affinity for the CB2 receptor, which is primarily found in the peripheral nervous system, immune system, and gastrointestinal system. The CB2 receptor is involved in the regulation of pain, inflammation, and immune response. O-2694 has a lower affinity for the CB1 receptor, which is primarily found in the brain and is responsible for the psychoactive effects of cannabis.

In animal studies, O-2694 has been shown to have analgesic effects, particularly against "atypical" pain types such as hyperalgesia and allodynia. Hyperalgesia is an increased sensitivity to pain, while allodynia is a pain response to a normally non-painful stimulus. These types of pain are often resistant to treatment with traditional analgesics such as opioids.

Clinical significance

The selectivity of O-2694 for the CB2 receptor over the CB1 receptor may make it a promising candidate for the development of new analgesic drugs. By targeting the CB2 receptor, it may be possible to achieve pain relief without the psychoactive effects associated with activation of the CB1 receptor.

However, more research is needed to fully understand the potential benefits and risks of O-2694 and other CB2 receptor agonists. In particular, the variation in selectivity between species observed in studies of O-2694 highlights the importance of conducting research in humans.

See also

• Cannabinoid receptor
• Cannabinoid receptor agonist
• Hyperalgesia
• Allodynia